Shandong Xinhua Pharmaceutical's (HKG:0719, SHE:000756) calcium gluconate passed the consistency of quality and efficacy evaluation for generic drugs in China.
The drug is indicated for treating hand-foot weakness caused by calcium deficiency, acute hypocalcemia, allergic diseases, relief from fluorosis, and cardiac resuscitation, among other conditions.
The pharmaceuticals and chemical products company's shares closed over 3% higher on Tuesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。